Adheris Health (AHE) H1 2026 earnings summary

Executive summary

• Report covers the half-year ended 31 December 2025, following the sale of the Australian and New Zealand (ANZ) business and a company name change.

• Principal activities now focus on pharmacy-driven, digital patient engagement solutions in the US market.

• No dividends were paid, recommended, or declared during the period.

Financial highlights

• Revenue from continuing operations was $23.3 million, down from $45.7 million year-over-year due to the ANZ business sale.

• Net profit after tax was $7.35 million, up from $1.4 million, driven by a $17.5 million profit on the ANZ business sale.

• Excluding the gain on disposal, the group recorded a loss after tax of $10.1 million.

• Cash and cash equivalents at 31 December 2025 were $8.1 million, down from $10.3 million at 30 June 2025.

• Net assets increased to $8.94 million from $1.05 million at 30 June 2025.

Outlook and guidance

• Directors believe the group will continue as a going concern, supported by post-period receipt of $6.1 million holdback from the ANZ sale and cash flow forecasts.